Written by the Nuvirox Research Team
Key Points
- Every published study connecting NAD+ precursors to PCOS is currently in mice or cultured cells — no human trial results have been published yet.
- One human trial (NMN in women with PCOS) is registered and recruiting, but results aren't available.
- PCOS is a diagnosable endocrine condition that benefits from a workup with a doctor familiar with reproductive endocrinology — not a supplement search.
Short answer: not yet — everything published on NAD+ precursors and PCOS so far is animal or cell research, and the one human trial is still recruiting. If you have PCOS and came across claims that NAD+, NMN, or NR can help, it's worth knowing exactly how far the science has actually gotten, because right now it hasn't reached people at all.
What PCOS is and why NAD+ comes up
Polycystic ovary syndrome (PCOS) is a common endocrine disorder involving some combination of irregular ovulation, elevated androgen levels, and polycystic ovaries on ultrasound, often alongside insulin resistance and low-grade chronic inflammation. Researchers have become interested in NAD+ because PCOS involves mitochondrial dysfunction and oxidative stress in ovarian tissue — both processes where NAD+ availability plays a central role. The scientific rationale is genuinely reasonable. What's not yet established is whether raising NAD+ with a supplement changes anything measurable in a person with PCOS.
What the animal research actually shows
Several mouse studies published in 2024 and 2025 have looked at this directly. In one study using a hormone-induced PCOS mouse model, nicotinamide mononucleotide (NMN) reduced testosterone levels, improved ovarian health markers, and partially restored irregular cycles — though it did not fully normalize the reproductive cycle or lipid metabolism in these mice. A separate study using letrozole-induced PCOS in rats found that NMN reduced excess androgen and improved markers of ovarian function by suppressing an inflammatory pathway (NLRP3 inflammasome) linked to PCOS. A third line of research looked specifically at egg (oocyte) quality in PCOS mice and found that NMN supplementation restored NAD+ levels within oocytes, improved mitochondrial function, and enhanced developmental rates during in vitro maturation.
Study Snapshot — NMN in PCOS Mice
| Model | Letrozole-induced PCOS, mice/rats |
| Intervention | Nicotinamide mononucleotide (NMN) |
| Reported findings | Lower androgen, improved ovarian markers, partial cycle restoration |
| Species tested in | Rodents only — no human data yet |
The honest counterweight: this hasn't worked all the way, even in mice
It's worth being precise about the mouse data rather than rounding it up. In the letrozole-induced PCOS mouse study on bile acid and hormone metabolism, NMN treatment lowered androgen levels and partially restored bile acid metabolism — but the researchers explicitly noted it did not fully normalize the reproductive cycle or fully correct lipid metabolism. Even within the preclinical evidence, the effect is partial, not a full reversal of the condition. That matters, because "improved some markers in mice" is a genuinely different claim than "treats PCOS."
Where human research stands
As of this writing, there is one registered clinical trial (NCT05305677) evaluating NMN's effects on reproductive endocrine function, metabolism, inflammation, and reproductive outcomes in women with PCOS. It's designed to enroll women aged 20-40 who are diagnosed with PCOS by standard criteria. The trial has not yet published results. That means the honest, current state of human evidence for NAD+ precursors and PCOS is: none published. Everything else discussed above — the mouse and rat studies — is preclinical, which is an important early step in research but is not the same thing as evidence that something works in people.
Why this distinction matters for PCOS specifically
PCOS is diagnosed and managed differently depending on a person's goals — symptom control, fertility, metabolic risk reduction — and effective management typically involves things like metformin for insulin resistance, hormonal treatments for cycle regulation, lifestyle interventions, and sometimes fertility-specific treatments if pregnancy is a goal. These have real human trial evidence behind them. Substituting an unproven supplement claim for an actual PCOS workup and management plan could mean missing out on treatments that are known to work, or missing important related health monitoring (PCOS carries elevated risk for insulin resistance and cardiovascular risk factors that benefit from regular screening).
What NAD+ supplementation won't do for PCOS right now
Based on the current evidence, an NAD+ precursor should not be expected to treat PCOS, restore ovulation, lower androgen levels, or improve fertility in a person — none of that has been tested in humans yet. It may still be reasonable to take for its studied effects on general cellular NAD+ levels, but that's a distinct claim from a PCOS-specific benefit.
Frequently asked questions
Has NMN or NR been tested in women with PCOS?
Not with published results yet. One human trial is registered and recruiting (NCT05305677), but as of this writing no results have been published. All current evidence comes from mouse and rat models.
If the mouse data looks promising, why does that matter less than I'd think?
Animal studies are a genuinely important early step, but a large share of interventions that work in mice never replicate the same way in humans, due to differences in dose, metabolism, and biology. Mouse data can justify running a human trial — it can't substitute for one.
What does have good evidence for managing PCOS?
Metformin for insulin resistance, combined hormonal contraceptives or other hormonal treatments for cycle regulation and androgen symptoms, structured weight management where relevant, and fertility-specific treatments (like letrozole) if pregnancy is a goal all have real trial evidence. A doctor experienced in PCOS management can tailor this to your specific presentation and goals.
Should I wait for the human trial results before trying an NAD+ supplement for PCOS specifically?
If your goal is a PCOS-specific benefit, yes — there's currently nothing to act on. If you're interested in an NAD+ precursor for general cellular energy reasons unrelated to PCOS, that's a separate decision with its own evidence base to evaluate on its own terms.
FROM NUVIROX
Why we formulated NAD+ Restore
We built NAD+ Restore for general cellular energy support — not as a PCOS treatment, since human trials in this specific area don't exist yet. Each 2-capsule serving delivers 500 mg of Nicotinamide Riboside Chloride, one of the two most-researched NAD+ precursors, within the dose range used in published human trials, alongside 150 mg trans-resveratrol and 50 mg quercetin, polyphenols studied alongside NAD+ pathways for cellular health support. 10 mg of galactomannans from fenugreek is included to support absorption.
Backed by a 60-day money-back guarantee — long enough to actually evaluate it the way the research says you should.
Learn more about NAD+ Restore →The bottom line
PCOS and NAD+ has a genuinely interesting research story building in mice and rats, with plausible mechanisms around mitochondrial function and inflammation in ovarian tissue. But it is, right now, entirely preclinical — no human trial results exist, and one registered human trial is still recruiting. If you have PCOS, the responsible next step is a workup and management plan with a doctor experienced in reproductive endocrinology, not a supplement purchase based on mouse data. Related reading: NAD+ and fertility/egg quality and NAD+ and inflammation.
References
- Effect of NMN (Nicotinamide Mononucleotide) on Polycystic Ovary Syndrome. ClinicalTrials.gov Identifier: NCT05305677. Status: recruiting.
- Fan Y, et al. Reverse effects of nicotinamide mononucleotide supplementation on declining quality of oocytes with polycystic ovary syndrome. FASEB J. 2025. PMC12272325.
- Nicotinamide mononucleotide attenuates hyperandrogenism in a polycystic ovary syndrome-like rat model by suppressing NLRP3 inflammasome-mediated granulosa-cell pyroptosis. J Ovarian Res. 2026.
- Nicotinamide mononucleotide alleviates bile acid metabolism and hormonal dysregulation in letrozole-induced PCOS mice. PMC11673032.
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This article is for informational purposes only and is not a substitute for professional medical advice.